NCT02272790 2023-10-03
Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
AstraZeneca
Phase 2 Completed
Clinical Trials
6 trialsNCT05201001 2023-09-11
APX005M
Nordic Society of Gynaecological Oncology - Clinical Trials Unit
Phase 2 Withdrawn
NCT04348032 2022-03-31
APPROVE
ChineseAMS
Phase 2 Unknown
NCT04887961 2021-08-09
MITO36
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Phase 2 Unknown
NCT04983550 2021-07-30
Efficacy and Safety of SG001 Combined With PLD in Patients With Platinum-resistant Relapsed EOC
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 2 Unknown
NCT01991210 2017-08-21
A Study of DNIB0600A in Comparison With Pegylated Liposomal Doxorubicin (PLD) in Participants With Platinum-Resistant Ovarian Cancer (PROC)
Genentech, Inc.
Phase 2 Terminated